KUALA LUMPUR: RHB Research has upgraded Duopharma Biotech to Buy from Sell with a new discounted cashflow-derived target price of RM4 from RM3.30 on the clarity of its Covid-19 vaccine participation in Malaysia.
The research house said on Thursday Duopharma’s prospects of participation in the vaccine had increased significantly after the government’s announcement on Tuesday.
It also pointed out the company’s human insulin contract has also been extended.
RHB Research noted a news report Science, Technology and Innovation Minister Khairy Jamaluddin as saying: “the next could be Duopharma as the company is in talks with a Russian vaccine candidate”.
Lynas waste disposal plant: Why did KJ ignore DOE red flags?
Published
Modified14 Jan 2021, 3:26 pm
A
-
Semambu assemblyperson Lee Chean Chung has urged Science, Technology and Innovation Minister Khairy Jamaluddin to explain why the site for Lynas’ permanent disposal facility (PDF) was approved despite public health concerns.
The Lynas PDF is to be located in Bukit Ketam in Kuantan, Pahang.
Putrajaya previously instructed Lynas to build a PDF for water leach purification (WLP) residue by March 2021 or risk losing its operating licence. WLP is controversial due to its radioactive nature.
In a statement today, Lee highlighted the Pahang Department of Environment’s (DOE) written reply to his question to the Pahang State Assembly.
KUALA LUMPUR (Jan 14): As two of Malaysia s closest neighbours, Singapore and Indonesia, kicked off their vaccination programmes, Science, Technology and Innovation Minister Khairy Jamaluddin wrote a blog post to give an update on what Malaysia s vaccine procurement process is like why it is not slow in getting its vaccines and the delivery schedule that Malaysians can expect. Khairy is also the co-chair of the Special Committee on Ensuring Access To Covid-19 Vaccine Supply.
Below is his blog post, reproduced in full:
An Update on Vaccine Procurement
2021 will be the year of vaccination, bringing with it some light at the end of the COVID-19 pandemic. As more countries start receiving and rolling out their vaccination programmes, many Malaysians have asked for updates on our vaccine supply. As co-chair of the special COVID-19 vaccine committee (JKJAV), I want to give you some updates.
channel for the latest stories and updates.
On Tuesday (12 January), Malaysian pharmaceutical group, Pharmaniaga Bhd announced that it had signed a deal with Chinese pharmaceutical company Sinovac Biotech Ltd to not only purchase their Covid-19 vaccine, but also the rights to manufacture it domestically.
While initially, this sounds like a great opportunity for the local pharmaceutical industry, recent reports of the vaccine’s reduced efficacy have caused some to question the decision.
Pharmaniaga’s deal with Sinovac for Covid-19 vaccines
According to Pharmaniaga’s announcement, they have signed an agreement with Sinovac to purchase 14 million doses of Covid-19 vaccines and carry out the final “fill and finish” stage of the manufacturing process domestically.